%0 Journal Article
%T The safety and tolerability of FE 100 C-D chemotherapy in a non-trial population of node positive breast cancer compared to PACS-01 trial group; Salmaniya Medical Complex experience
%A Aysha AL Zaman
%A Yahya AL Zaman
%A Entisar AL Zaman
%J Clinical Cancer Investigation Journal
%@ 2278-0513
%D 2013
%V 2
%N 3
%R 10.4103/2278-0513.119261
%P 202-206
%X Introduction: In our institution, adjuvant taxanes are currently offered to fit node-positive breast cancer patients who are either Her2 positive (any ER/PR) or triple negative (ER/PR/Her2 negative). The FE 100 C-D (FE100C × 3 → docetaxel 100 mg/m 2 × 3) regime, based on the PACS 01 trial1 is used. Materials and Methods: We retrospectively audited our experience with FE 100 C-D at Salmaniya Medical Complex. Over a 2-year-period, 100 patients commenced adjuvant FE100C-D chemotherapy. Data was matched with the FE 100 C-D arm of the PACS 01 trial. Results: Median age was 54 years. Twenty-six patients (26%) had ≥1 episode of febrile neutropenia (FN), including one fatal episode; 29% patients required treatment interruption ≥1 week; 30% patients had dose reductions; and 30% patients received < 90% dose intensity of docetaxel. Conclusion: The FN rate was substantially higher and docetaxel dose intensity substantially lower in our unselected sample of patients than in the trial population, this "real-life" data demonstrates the problems of applying clinical trial data to the more generalised patient population. Meanwhile, the routine use of prophylactic G-CSF support with this protocol is warranted.
%U https://ccij-online.org/article/the-safety-and-tolerability-of-fe-100-c-d-chemotherapy-in-a-non-trial-population-of-node-positive-breast-cancer-compared-to-pacs-01-trial-group;-salmaniya-medical-complex-experience-116